Form D · Biotechnology
Deverra Therapeutics, Inc.
Seattle, WA · CIK 0001822782
Offering snapshot reported Sep 18, 2023 · SEC filing
- Reported sold
- $2.39M Offering amount: $2.39M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $2.39M Reported outside-investor minimum
- First sale
- Sep 8, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 18, 2023 | Initial | $2,388,889 | No comparison | 1 | SEC filing |
| Aug 27, 2020 | Initial | $75,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b, 3C, 3C.1
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $80K
- Finders' fees
- $0
- Form D file number
- 021-492316
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| RBC Capital Markets | 31194 |
Source: Form D, filed Sep 18, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Colleen Delaney | Executive |
| Michael Yurkowsky | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1600 Fairview Avenue East Suite 300
Seattle, WA, 98102
Seattle, WA, 98102